Drugs / 9 valent human papillomavirus vaccine
9 valent human papillomavirus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04255849 | Feb 2021 → Jul 2026 overdue | HIV infectious disease, human papilloma virus infection, oropharynx squamous cell carcinoma | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-07-27 | Merck Sharp & Dohme LLC | Regulatory Merck Announces Second-Quarter 2018 Financial Results merck.com ↗
The FDA granted Priority Review and set a PDUFA date of Oct. 6, 2018. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-27 | Merck Sharp & Dohme LLC | Merck Announces Second-Quarter 2018 Financial Results merck.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9 valent human papillomavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04255849 ↗ |
| Known as | 9vHPV | “9-valent HPV (9vHPV) vaccine” PMID 40609265 ↗ Jul 2025 |
| Known as | 9vHPV vaccine | “9-valent HPV (9vHPV) vaccine” PMID 40609265 ↗ Jul 2025 |
| Known as | Gardasil-9 HPV vaccine | “Gardasil-9 HPV vaccine” NCT04255849 ↗ |
| Known as | nine-valent HPV vaccine | “This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult...” NCT04255849 ↗ |
| Modality | Vaccine | “9-valent HPV (9vHPV) vaccine” PMID 40609265 ↗ Jul 2025 |